Adherent Monomer-Misfolded SOD1 by Watanabe, Yasuhiro et al.
Adherent Monomer-Misfolded SOD1
Yasuhiro Watanabe*, Eri Morita, Yasuyo Fukada, Koji Doi, Kenichi Yasui, Michio Kitayama, Toshiya
Nakano, Kenji Nakashima
Department of Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, Yonago, Japan
Abstract
Background: Multiple cellular functions are compromised in amyotrophic lateral sclerosis (ALS). In familial ALS (FALS) with
Cu/Zn superoxide dismutase (SOD1) mutations, the mechanisms by which the mutation in SOD1 leads to such a wide range
of abnormalities remains elusive.
Methodology/Principal Findings: To investigate underlying cellular conditions caused by the SOD1 mutation, we explored
mutant SOD1-interacting proteins in the spinal cord of symptomatic transgenic mice expressing a mutant SOD1,
SOD1
Leu126delTT with a FLAG sequence (DF mice). This gene product is structurally unable to form a functional homodimer.
Tissues were obtained from both DF mice and disease-free mice expressing wild-type with FLAG SOD1 (WF mice). Both
FLAG-tagged SOD1 and cross-linking proteins were enriched and subjected to a shotgun proteomic analysis. We identified
34 proteins (or protein subunits) in DF preparations, while in WF preparations, interactions were detected with only 4
proteins.
Conclusions/Significance: These results indicate that disease-causing mutant SOD1 likely leads to inadequate protein-
protein interactions. This could be an early and crucial process in the pathogenesis of FALS.
Citation: Watanabe Y, Morita E, Fukada Y, Doi K, Yasui K, et al. (2008) Adherent Monomer-Misfolded SOD1. PLoS ONE 3(10): e3497. doi:10.1371/
journal.pone.0003497
Editor: Ulrich Mueller, University of Giessen, Germany
Received August 14, 2008; Accepted September 22, 2008; Published October 23, 2008
Copyright:  2008 Watanabe et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: A Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan. A Grant from the Research
Committee of CNS Degenerative Diseases, Ministry of Health, Labour and Welfare of Japan. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: yawatana@med.tottori-u.ac.jp
Introduction
Amyotrophic lateral sclerosis (ALS), a progressive and fatal
disorder of the central nervous system (CNS), selectively affects
both upper and lower motor neurons in the cerebral cortex, brain
stem and spinal cord. Approximately 10 percent of ALS cases are
of the hereditary type (familial ALS; FALS), and about 20% of
FALS cases are associated with Cu/Zn superoxide dismutase
(SOD1) mutations [1,2]. Since the first report of a link between the
SOD1 mutations and FALS [3], more than 130 different
mutations have been reported [1,2]. Two leading hypotheses
have been advanced to explain the apparent ‘‘toxic gain of
function’’ of the mutant SOD1 protein [1,2]. The first of these, the
‘‘aggregation toxicity’’ hypothesis, suggests that mutant SOD1
becomes misfolded and oligomerized to form intracellular
aggregates, which then diminish the availability of essential
proteins for normal cellular function. The second hypothesis, the
‘‘oxidative damage’’ theory, conjectures that toxicity is caused by
the aberrant chemistry of the metal-binding sites of the mutant
SOD1, such as peroxidase or superoxide-reducing activities and
peroxynitrite catalysis. These hypotheses, however, are unable to
explain the multiple perturbations of cellular function identified in
FALS, including excessive excitatory toxicity, protein misfolding,
impaired energy production, abnormal calcium metabolism,
altered axonal transport, activation of proteases and nucleases,
and so on [1,2]. Furthermore non-neural cell populations
substantially contribute to motor neuron degeneration [4]. So
far there is no single pathway that explains such diverse cellular
consequences.
To investigate the nature of the mutant SOD1, we have studied a
SOD1 mutation characterized by a 2-bp deletion at codon 126
(SOD1
Leu126delTT) [5,6]. The mutation causes a frame shift and
results in a premature stop codon. The SOD1
L126delTT consists of
only 130 amino acids, compared to the 153 found in the wild type
[7]. The SOD1
L126delTT does not form a functional dimer as it does
in the case of normal SOD1 [8]. As a consequence, the quantity of
the SOD1
L126delTT mutant is a mere trace in patients with this
mutation[6,9].Thisobservationalsoholdstrueforoverexpressionof
SOD1
L126delTT intransgenic mice[10]. Our particular questions are
how more than 130 different SOD1 mutations all result in motor
neuron degeneration, and how a low level of mutant SOD1
expression,like SOD1
L126delTTleads to FALSin a similar manner to
high level expression that is seen with point mutations. Importantly,
homodimeric mutant SOD1 forms unnatural, partially folded
monomeric and soluble oligomeric intermediates before aggregation
in vitro [11] and in vivo [12]. Moreover, the soluble fibrous oligomers
could be far more toxic than the visible inclusions [13]. If a small
population of monomer-misfolded SOD1 is pathogenic in FALS,
analysis should be difficult when using homodimeric mutant SOD1
like the mutant SOD1
G93A as the majority of homodimeric protein
has merely a bystander role. Meanwhile transgenic mice expressing
the SOD1
L126delTTcould be an ideal model for analyzing the disease
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3497process of FALS as the SOD1
L126delTT protein is inherently
monomeric. This thus enables the important capability of seeking
the proteins that specifically interact with mutant SOD1. Using a
pull-downproteomicmethod,wepresentherethatmanyinadequate
protein-protein interactions are seen in the SOD1
L126delTT.
Results
Proteomic Analyses
Two lines of transgenic mice were used in this experiment.
The DF (deletion, FLAG) mice ubiquitously expressed the
SOD1
L126delTT with a FLAG sequence at C terminal, as did the
WF (wild type, FLAG) mice exhibiting a wild-type human SOD1
with the FLAG sequence [10] (Fig. 1). The DF mice showed ALS-
like symptoms, while the WF mice did not. As a further negative
control, wild-type C57BL/6 (NTG) mice were subjected to the
same analysis. The tissues were solublized, and the FLAG-tagged
SOD1 and cross-linking proteins were selectively enriched using a
FLAG affinity purification system. After digestion in a single tube,
the samples were subjected to liquid chromatography-tandem
mass spectrometry (LC-MS/MS) analysis, whereupon each
protein was identified after reference to a protein database.
Proteins whose peptide hit score was less than 2 were eliminated.
In symptomatic DF mice aged 145 days, 34 proteins (or subunits)
were unambiguously identified by the analysis (Table 1). These
proteins could be grouped into 7 approximate functional
categories: heat shock proteins (HSPs) and protein degradation;
ATPases; glycogenolysis, glycolysis and TCA cycle; cytoskeleton
and structure; membrane and protein trafficking; protein biosyn-
thesis; and others (Table 1). Solute carrier family 25 (SLC25)
proteins (members 4 and 5) categorized as ‘‘others’’ were involved
in ATP transport from mitochondria to cytosol [14]. In the WF
analysis identified proteins were mouse SOD1, keratin and 2 of the
heat shock protein 70 member proteins. Consistent with our
previous observation, the WF SOD1 interacted with an intrinsic
mouse SOD1 during dimer formation, whilst the DF did not. A
mere 3 proteins were singled out in the NTG mice and of these
only b tubulin overlapped with the DF mouse set.
To confirm if region and age specificities existed in the DF mice,
a proteomic profile of spinal cords aged 145 days was compared
with similar profiles of spinal cords aged 35 days (presymptomatic)
and the cerebellum aged 145 days (Table 2). The results indicated
that the interacting protein groups were essentially similar to each
other, while the number of interacting proteins in the spinal cord
age 145 days exceeded that of the others. Ubiquitin carboxy-
terminal hydrolase L1 (UCHL1), ATP synthase b and c subunits, a
(non-neuron) enolase (Eno1), cofilin 1, latexin and SLC25 members,
along with someotherproteins werespecific for thesymptomatic DF
spinal cords (Table 2). Intriguingly, heat shock protein 70 (Hsp70), a
stress-inducible form of HSPs, was absent only in the symptomatic
DF spinal cords. Meanwhile, possessing over 85% homology with
Hsp70, constitutively expressed housekeeping chaperone heat shock
cognate 70 (Hsc70) was recognizable in all samples (confusing
terminology and the function of Hsp70 family proteins are reviewed
by Daugaard et al [15]).
Immunoprecipitation and western analyses
The DF mutant SOD1 represents a relatively small proportion
of the total SOD1 content of the spinal cord compared to both the
WF and wild-type mouse SOD1s (Fig. 2A–C). WF SOD1 interacts
with mouse intrinsic SOD1 (Fig. 2B). Among the DF-mutant
SOD1-interaction proteins (subunits), we especially focused on
interactions with the Na/K ATPase subunit a (ATP1A) and ATP
synthase b subunit (ATP5B). This is not only because they showed
high hit scores in the proteomic analysis, but also because they are
among the most important proteins necessary for cellular energy
homeostasis, and have previously been reported to be seriously
compromised in SOD1
G93A mice. Hsp70 and Hsc70, also
previously described as direct interactors with mutant SOD1,
were also subject to the analysis. Consequently, immunoprecipi-
tation experiments were performed using antibodies for ATP1A,
ATP5B, Hsp/Hsc70, or FLAG (Fig. 2E–I). After SDS electro-
phoresis, proteins were also probed for using antibodies against
SOD1, ATP1A, or Hsp/Hsc70 (Fig. 2E–I). The DF mutant
SOD1 but not WF protein has been shown to directly interact with
ATP1A and ATP5B (Fig. 2E, F, H, and I). Our analysis also
revealed a tight link between the DF mutant SOD1 and Hsp/
Hsc70 (Fig. 2G).
Immunohistochemistry
Immunohistochemical analysis was performed using the afore-
mentioned antibodies for ATP1A and ATP5B, as well as for a
number of respective subunits: Na/K ATPase subunit b (ATP1B)
and ATP synthase a subunit (ATP5A). Immunoreactivity for
ATP1A was similar in both the DF (Fig. 3A) and NTG (Fig. 3B)
mice. Meanwhile, immunoreactivity for ATP1B was invariably
decreasedinDFmice(Fig.3C)comparedtothe NTGmice(Fig.3D).
As ATP5A and ATP5B are the major components of the
mitochondrial ATP synthase, spotty expression is seen in the cell
body in NTG mice (Fig. 3E and G). Reduced expression of
ATP5A was evident in the DF mice (Fig. 3F), while the expression
of ATP5B was unaltered between both groups (Fig. 3G and H).
Discussion
We first hypothesized that there could be a specific ligand
protein(s) for the mutant SOD1 only in the spinal cord and motor
cortex. However, the results instead revealed that the mutant
SOD1-interacting proteins were rather ubiquitously expressed. As
Rakhit et al. suggested [12], the hydrophobic residues of the
mutant SOD1, normally buried in the dimer interface, would be
responsible for the interaction with a broad spectrum of proteins.
Also unexpectedly, many of the mutant SOD1-interacting proteins
were involved in ATP production and utilization (Table 1).
Because ATP is the ‘‘energy currency of the cell’’ through which a
diverse range of cellular activities are mediated, decreased ATP
production and/or inability of ATP utilization inevitably cause
Figure 1. Computer assisted simulation of the FLAG-tagged
SOD1 proteins. Simulation models of the FLAG-tagged SOD1s were
constituted using Discovery Studio 1.7 software (Accelrys, USA) from
Protein Data Bank (PDB) data; 1MFM for DF, 2V0A for WF as templates.
The red parts indicate the FLAG epitopes. The DF mutant SOD1 possibly
exposes a hydrophobic structure, which is normally buried by the dimer
interface.
doi:10.1371/journal.pone.0003497.g001
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molecules, we especially focused on two ATPases: Na/K ATPase
and ATP synthase. It is not only because they show high
probability scores and high peptide hits in the proteomic analyses,
but also because Na/K ATPase and ATP synthase are the largest
ATP consumers and largest ATP producers in the cell,
respectively. Moreover, as described later, the impairment of the
ATPases is methodologically endorsed by a number of previous
observations using the SOD1
G93A mouse model, a standard
murine ALS model. So far there is no sufficient explanation
elucidating the connection between mutant SOD1 and these
ATPases. The direct protein-protein interactions presented here
should be a convincing interpretation.
Na/K ATPase
Previous reports indicate that Na/K ATPase enzymatic activity
decreases significantly in the motor neurons of SOD1
G93A mice
and chronically from the presymptomatic stage until the end stage
[16]. Another report suggests that reduction in Na/K ATPase
activity extends throughout the spinal cord of SOD1
G93A mice
[17]. Na/K ATPase consumes 50% of the energy supply in the
CNS [18,19]. Harnessing the energy of ATP hydrolysis, the Na/K
antiporter transports K+ ions into and Na+ ions out of the cell.
This creates an electrochemical gradient across the plasma
membrane that secondarily enables the transportation of ions,
amino acids, glucose, and so on. Inhibition of the Na/K ATPase
causes neurons to become incapable of maintaining their cellular
volume, resulting in neuronal swelling [20]. It is reported that
damage to the Na/K ATPase itself and/or subsequent impair-
ment by the subnormal ATP production render neurons more
sensitive to glutamate excitotoxicity [2,17,21,22]. The Na/K
ATPase consists of an a (ATP1A) and a b (ATP1B) subunit. The
ATP1A, which is the catalytic subunit where ATP binding sites are
located, is sensitive to damage by free radicals and other oxidative
stresses [17], and it is also a target of peroxynitrite [20]. In the
CNS, a1 is ubiquitous, while a2 is expressed in glial cells and a3i s
expressed in neurons. All of these were shown to interact with DF
mutant SOD1 in our experiment. Moreover, the altered
immunoreactivity for ATP1B in the DF mice was clearly evident
using immunohistochemical methods.
ATP synthase
It is evident that a fraction of SOD1 is localized in the
mitochondria [23,24]. ATP synthase, the final enzyme in the
respiratory chain, resides in the mitochondrial inner membrane
and generates most of the ATP in aerobic tissues. Our proteomic
analysis also shows that a (ATP5A), b (ATP5B) and c subunits of
ATP synthase interact with the mutant SOD1. These 3 subunits,
belonging to the F1 catalytic core of ATP synthase, play a key role
in energy production. Our results also indicate a tendency toward
ATP reduction in the DF spinal cord. Immunohistochemical
analysis revealed a marked reduction of ATP5A expression in the
spinal cord of DF mice. While little is known about the role of
ATP5A in FALS pathogenesis, growing evidence indicates that
ATP5B is one of the stress-prone proteins in G93A mice. The
quantity of ATP5B is already decreased in the spinal cord of
SOD1
G93A mice during the presymptomatic stage [25], as well as
in the mitochondrial fraction of end-stage SOD1
G93A mice [26].
The fact that ATP5B is overnitrated in SOD1
G93A mice before
symptom onset may strongly influence interactions between
subunits and impair the complex machinery of ATP production
[27]. These results may help to explain the reduction of ATP
synthesis in spinal cord mitochondria of symptomatic SOD1
G93A
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and spinal cord of presymptomatic SOD1
G93A mice [21].
Conclusion
A wide range of proteins were shown to interact with the
monomer-misfolded mutant SOD1, which is not necessarily an
exceptional form in FALS-associated homodimeric mutant
SOD1s. The mutant SOD1-interacting proteins might be
compromised in their innate functions in a normal cellular
compartment by bonding with the mutant SOD1. Among them,
the impairment of Na/K ATPase and/or ATP synthase alone
could cause devastating cellular consequences.
Materials and Methods
Transgenic mice
Two lines of transgenic mice were used in this experiment.
The DF (deletion, FLAG) mice ubiquitously expressed the
SOD1
L126delTT with a FLAG sequence at C terminal, as did the
WF (wild type, FLAG) mice exhibiting a wild-type human SOD1
with the FLAG sequence [10] (Fig. 1). The DF mice showed ALS-
like symptoms, while the WF mice did not. As a further negative
control, wild-type C57BL/6 (NTG) mice were subjected to the
same analysis. The homozygotes of DF mice begin to show clinical
symptoms at around 140 to 147 days of age. After the disease
Figure 2. Immunoprecipitation and western blot analyses of mouse spinal cords. The FLAG-tagged SOD1 and the ligand proteins were
immunoprecipitated using the FLAG affinity resin and detected by the anti FLAG antibody (A) and anti-SOD1 polyclonal antibody (uSOD1) that
recognizes both human and mouse SOD1 (B). The DF mutant SOD1 shows a distinct single band (A and B). In contrast, the WF shows high molecular
weight bands (A) and a low molecular weight band which is possibly the mouse intrinsic SOD1 (B), indicating that the WF forms the heterodimer
with the mouse SOD1. Crude spinal cord extracts (5% input) were analyzed using antibodies for human specific SOD1 (hSOD1) (C) and for uSOD1 (D).
Compared to the WF, the amount of the DF SOD1 protein is considerably lower (C). The WF itself is lower still compared to the mouse intrinsic SOD1
(D). The immunoprecipitation products with the FLAG were analyzed by antibodies for ATP1A (E) and Hsp/Hsc70 (G). In this analysis, only the DF
preparations show the presence of ATP1A (E). In the Hsp/Hsc70 analysis in (G), there are non-specific precipitations also in WF and NTG. In contrast,
the immunoprecipitated samples for ATP1A (F), Hsp/Hsc70 (H) and ATP5B (I) were analyzed using antibodies for hSOD1 (F) or uSOD1 (H and I).
Correspondingly, the human form of SOD1 is only seen to be co-immunoprecipitated in DF preparation (F, H and I). Lanes from the left are: DF, WF,
NTG, and a purified human SOD1 (A, B, C, D, F, H, and I); and DF, WF, NTG, and a crude soluble fraction of NTG mice (E and G).
doi:10.1371/journal.pone.0003497.g002
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analyzed the DF mice around the age of 145 days, beginning to
show distinct motor neuron symptoms but without emaciation, as
well as presymptomatic DF mice aged 35 days.
All animal experiments were carried out in accordance with
Guidelines for Animal Experimentation at the Faculty of Medicine,
Tottori University, and all efforts were made to minimize animal
numbers and suffering during the experiments. Mice were sacrificed
by intraperitoneal injection of pentobarbital. The spinal cords were
rapidly removed (n=5 in case of DF mice age 35, otherwise n=4)
and immediately stored in liquid nitrogen until use.
Pull-down LC-MS/MS analysis
Spinal cords as well as cerebellum were suspended 1:10 (w/v) in a
lysis buffer (0.15 M NaCl, 10 mM Tris-HCl and 1% Triton X-100,
pH 7.4) containing a cocktail of protease inhibitors (Roche
Diagnostics, Switzerland) and homogenized [28]. After the brief
(1 second, 3 times) sonication, the cell lysates were centrifuged for
15 min at 14,000 rpm to remove cell debris. Each sample contained
0.8 ml of tissue extract with a total protein concentration of between
5and6 mg/ml.Afterthepre-clearusingaproteinA/Gplus-agarose
(sc-2003, Santa Cruz Biotechnology, USA), the supernatant was
incubated with an anti-FLAG M2 affinity gel (Sigma, USA). The
immunoprecipitated samples were eluted with 36FLAG peptide
(Sigma). The eluted samples were digested by trypsin in a single tube
and the resulting mixtures of peptides were directly subjected to the
LC-MS/MS analysis system (Zaplous, AMR, Japan) using Finnigan
LTQ (ThermoFisher Scientific, USA). The protein annotation data
was queried in the NCBI_nr database reconstructed for mouse (Jan.
10, 2007) using Bioworks (Ver. 3.3).
Immunoprecipitation and western analysis
CNS tissue extracts were prepared in the same way for proteomic
analysis. Immunoprecipitation was performed using the anti-FLAG
M2 affinity gel or otherwise with a combination (10 mg antibody/
10 ml resin) of protein A/G plus-agarose and an anti-Na/K-ATPase
a, rabbit polyclonal antibody (H-300, Santa Cruz biotechnology,
USA) that recognizes all Na/K-ATPase a isoforms; anti-Hsp72/73
mouse monoclonal antibody (W27, Calbiochem, USA) that
recognizes both Hsp70 and Hsc70; or anti-ATP synthase beta
mouse monoclonal antibody (ab5432, abcam, USA). Immobilized
antibody/bound antigen was collected by centrifugation (5,000 g for
1 min). The resin pellet was washed three times with the lysis buffer,
and the antibody/antigen protein complex was eluted with
36FLAG peptide or with 40 ml 0.1 M glycine-HCl, pH 3.0. In
the pH elution, the eluted sample was neutralized by the addition of
10 ml of 1 M Tris-HCl and 1.5 M NaCl, pH 7.4.
Immunoblot was performed using a rabbit anti-Cu/Zn
superoxide dismutase polyclonal antibody (SOD-101, Stressgen,
USA) for both human and mouse SOD1, rabbit anti superoxide
dusmutase 1 (SOD1) human specific polyclonal antibody
(AB5480, Chemicon, USA), monoclonal anti-FLAG M2 antibody
(Sigma), or otherwise using the aforementioned antibodies for
ATP1A and Hsp/Hsc70. Aliquots of 10 mg were electrophoresed
and transferred onto PVDF membranes (Hybond-P; Amersham
Biosciences, UK). For chemiluminescense detection, we used a
Figure 3. Immunohistochemistry. Fixed-frozen sections of the spinal cord (10 mm thickness) derived from symptomatic DF mice at 145 days of
life (A, C, E, and G) and age-matched NTG mice (B, D, F, and H) were stained with antibodies for ATP1A (A and B), ATP1B (C and D), ATP5A (E and F),
ATP5B (G and H). The tissue was counterstained with hematoxylin. Bar: 200 mm.
doi:10.1371/journal.pone.0003497.g003
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advance and rabbit IgG TrueBlot (eBioscince, USA).
Immunohistochemistry
Symptomatic DF mice at ,145 days of life (within a week of
symptom onset) as well as age-matched NTG mice were sacrificed
and perfused with 4% paraformaldehyde. Fixed-frozen sections of
the spinal cord (10 mm thickness) were stained immunohistochem-
ically by the streptavidin-biotin method using the aforementioned
antibodies for ATP1A and ATP5B, as well as anti-Na/K ATPase
b1 monoclonal antibody (464.9, Santa Cruz biotechnology, USA)
for ATP1B, and ATP5A monoclonal antibody (15H4, Santa Cruz
biotechnology, USA). The tissue was counterstained with
hematoxylin.
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